Compare HUN & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUN | MLTX |
|---|---|---|
| Founded | 1970 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2004 | 2020 |
| Metric | HUN | MLTX |
|---|---|---|
| Price | $8.16 | $10.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 15 |
| Target Price | $10.62 | ★ $28.54 |
| AVG Volume (30 Days) | ★ 2.5M | 1.9M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,683,000,000.00 | N/A |
| Revenue This Year | $8.52 | N/A |
| Revenue Next Year | $2.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.30 | $8.80 |
| 52 Week High | $16.09 | $23.29 |
| Indicator | HUN | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.39 | 29.80 |
| Support Level | $8.10 | N/A |
| Resistance Level | $9.99 | $19.24 |
| Average True Range (ATR) | 0.31 | 0.66 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 6.36 | 20.60 |
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. The product portfolio of the company comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, and others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. The company derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.